Tag: jkscientist

  • ‘Our Gut  Is Our Second Brain’

    [ad_1]

    Kashmir neuroscientist, Dr Zahoor Shah, currently teaching at the University of Toledo, Ohio, is investigating the Gut-Brain axis in understanding various brain disorders, including Alzheimer’s disease. His research sees the gut as a major player in various diseases as the key organ is a universe of good and bad bacteria, he reveals in a detailed interview 

    TheNewsCaravan (KL)Is it true that most of the innovations and discoveries are logical explanations of conventional wisdom that humans already know?

    DR ZAHOOR SHAH (DZS): Yes, You said it right. There is a role of human beings behind all the advancements in the world, even if you talk about artificial intelligence. All the inventions and technologies in the present world are because of human effort. Even if we talk about genetics, it was not taken into consideration in the past, but now it has changed science to a whole new level. For example, in the last ten years, there has been a tremendous amount of research on microbiota (bacteria in human intestines), which were not previously distinguished that much. Then, with time, scientists were able to discover their importance.

    Overall, science has moved from conventional to new inventions. Scientists were able to discover new signalling pathways and causes of diseases in the body. There is a substantial increase in knowledge about medical science and a lot of enhancement in human health with technological advancements. Technology has helped us a lot. Now, we can isolate a minute gene from a cell and amplify it. We have also learned about the causes of diseases and found a cure that humans suffered through. Earlier, people would die young and nobody could explain why. Now we have progressed, and conditions can be identified earlier, and lives can be saved. It has led to longer life spans and a concept of slowing the ageing process and identifying causes that accelerates ageing and related diseases.

    KL: How has your journey been till now and what were the struggles and milestones that you encountered from Srinagar to Ohio?

    DZS: I did my schooling up to tenth standard at Shaheen Public School, and then twelfth from MP Higher Secondary School, Srinagar. I graduated with a BSc from SP College and worked part-time as a medical representative, where I became interested in drug discovery and development. That curiosity led me to pursue a Master’s degree in Toxicology at Hamdard University, Delhi. While pursuing my master’s, I got interested in research as I saw PhD scholars performing research in different areas of pharmacology and toxicology.

    Fortunately, I got a chance to do my research on Neurobehavioral systems under famous neuro-behaviourist Dr SB Vohra, who is not unfortunately with us now. After finishing my PhD, I got an opportunity to do my first postdoctoral training with Dr David Gozal at the University of Louisville, Kentucky, for two and a half years. I studied sleep apnoea and identified biomarkers in the urine sample of children. The idea was to develop a diagnostic kit in which we could use a child’s urine sample to detect whether the child is suffering from sleep apnoea instead of a child going through excruciating overnight sleep studies. We identified a few biomarkers, and my mentor, David Gozal, patented the concept.

    It is essential to mention that my PhD was on finding neuroprotective agents for ischemic brain injury. I was intrigued by the beneficial effects of natural plant products like green tea and Ginkgo biloba on human health. So I wanted to research whether these two natural products can help prevent stroke. Stroke is a leading cause of death and is caused by a clot that stops blood flow to the parts of the brain.

    This was a game changer in my career as this concept helped me to receive a grant award when I moved to Johns Hopkins University for my second postdoctoral training. My mentor at Johns Hopkins, Dr Sylvain Dore, suggested writing a grant proposal on a novel natural product that could help in stroke prevention. Since I had already studied Ginkgo Biloba, I proposed the concept and received a highly competitive grant award from the National Institute of Health, Pathway to Independence. We fed Ginkgo biloba to animals and experimentally induced a stroke to examine whether it could show protective effects. After receiving the grant, I moved to the University of Toledo in 2009, where I got an independent position as Assistant Professor. There, I developed new research ideas as my interest grew in understanding the proteins or genes that are beneficial or harmful during a stroke. My team, including PhD students and postdocs, identified a protein crucial in stroke pathology. As the study progressed, we discovered its role in increasing inflammation in the brain in other conditions.

    Here at the University of Toledo, I am in the Medicinal Chemistry Department and collaborated with a medicinal chemist. We synthesized a chemical molecule (drug molecule) against the gene we identified playing a crucial role in stroke pathology. We did preliminary studies using cell models of human haemorrhagic stroke and found the drug molecule is preventing neurons from the toxic effects of blood. Haemorrhagic stroke occurs when a brain blood vessel ruptures and causes bleeding. As a result, widespread neuro-inflammation ensues after the initial impact of bleeding. This is considered a debilitating disease, and around 50 per cent of patients remain immobilized for the rest of their lives.

    Dr Zahoor Shah e1677396662317
    Dr Zahoor Shah (University of Toledo, Ohio)

    Since there is no drug available to treat haemorrhagic strokes, our idea was to make a drug molecule for reducing neuroinflammation. First, we developed a concept and sent the proposal to the National Institute of Health for funding. Fortunately, we received approximately US 2 million dollars for the research and development of the drug molecule. This research is ongoing, and we have received a US patent on this invention.

    Our continuing efforts led my PhD students to research other conditions like age-related diseases and neuro-degenerative diseases that usually occur after the ’60s, such as Dementia, Parkinson’s disease, or Alzheimer’s disease. Most of these diseases have a single common component which is neuroinflammation. Therefore, we want to stop neuroinflammation so that old people become less prone to neurodegenerative diseases.

    Besides, we also saw that neuroinflammation might have origins in other organs of the body. Certain diseases like Obesity, Diabetes, or Rheumatoid Arthritis have inflammation spread throughout the body. These inflammatory compounds do not enter the brain because the Blood Brain Barrier keeps harmful substances from entering the brain. But with age, this barrier also gets groggy and all the harmful inflammatory components cross into the brain resulting in neuroinflammation. This led to another intriguing question on gut microbiota and whether it has any role in neuroinflammation. Our intestines provide a conducive environment for essential bacteria that thrive on the fermentation of non-digestible fibres.

    Conversely, people nowadays eat a lot of unhealthy Western food and fast food, which increases bad bacteria and decreases good bacteria in our gut, causing dysbiosis (an imbalance in the gut microbial community). Thus, we studied what effect gut dysbiosis will have on the brain, as it is well connected to the brain. For example, whenever we have to write an examination or make a presentation, we get nervous and anxious, which gives us a sense of butterflies in our stomach and results in a stomach ache or nausea. So, there is a bi-directional connection between our brain and gut. Therefore, we looked into what interchanges occur in the gut with ageing and its impact on our brain health.

    For the last 12 years, I have been studying peripheral inflammation and now got interested to learn the microbiota-brain-axis in ageing. We performed experiments on aged mice and induced experimental inflammation to see whether it would change the microbiota. So, it came to be true and we observed an increase in the bad bacteria which caused the inflammation. We also observed markers of other neurodegenerative diseases in the brain. With this, we figured out that people with Diabetes, Rheumatoid arthritis, Obesity, Parkinson’s disease, and Alzheimer’s may have microbiota dysfunction. Along with this, we also observed female animals having higher Alzheimer’s Disease markers. Females are known to have a higher risk of Dementia related to Alzheimer’s disease than men.

    We are currently working on the drug molecule, as I mentioned before and we are at an advanced stage of developing it.

    KL: What were the different takeaways from your research and is there anything as such that is available and in practice on the ground level?

    DZS: As I enunciated about my PhD research earlier, that was on Ginkgo Biloba. It is known to increase our memory. There have been many clinical trials in that aspect, but they didn’t prove successful. Patients above 70 years were recruited to see whether Ginkgo Biloba supplements would help enhance memory. I was at John Hopkins during this clinical trial, and our proposal of using a natural product for stroke prevention was fascinating and resulted in receiving the grant award. So, it was an outstanding achievement for me, as Gingko Biloba is already available in the market and has no side effects. If taken in minimal amounts has good health benefits. If at least 120 mg is taken daily, it can have good results and has no toxicity. This ground-breaking finding can benefit stroke prevention and help enhance memory in older people.

    The other important achievement is the drug we are developing for neuroinflammation. I stated before the drug received the US patent and is ready to proceed in clinical trials and get FDA approval for clinical use.

    KL: Subjecting to gut feeling or gut-brain axis, is it relevant to say that the brain has outsourced some of its functions to the gut? 

    DZS: That is an interesting question and an interesting idea to investigate. Our gut has major roles to play and is also considered a second brain because of its neural connections to the brain. The oesophagus and lining of the intestines to the rectum all have neural circuits that are controlled by the enteric nervous system (ENS), which is responsible for gastrointestinal behaviour. So, there is a bi-directional connection between the brain and the gut. Gut-brain-axis has many essential functions, including hormonal connections, and manage the immune system to some extent

    For example, if we talk about Autism Spectrum Disorder (ASD), it has been found that the root cause is gut dysbiosis. Other disorders like Anxiety, Depression, or weight gain have also been seen to occur because of gut bacteria dysbiosis. There have also been experiments on weight gain in which faecal samples of overweight patients were taken and then implanted in mice. It was observed that the mice also gained weight due to bad microbiota. With that observation, it was observed that gut microbiota not only deals with gastrointestinal behaviour but also increases weight. So, it denotes that if we have a healthy gut, it can also control our weight. There are also a lot of clinical trials and research going on faecal implantation from healthy persons to patients with gut dysbiosis and syndromes like inflammatory bowel syndrome or irritable bowel syndrome.

    KL: How sooner will we be able to see a shift in our routine toward something that is based on your path-breaking study?

    DZS: For now, there has already been awareness, and people are moving towards a healthy lifestyle. The major takeaway is to take healthy foods that are rich in fibre. Usually, when we have fibrous food, it does not get digested in the upper colon but gets assimilated in the lower colon. After the assimilation, the material is left for the good bacteria to maintain equilibrium in the gut.

    The drug molecule that I have invented may take time to come out. The least we can do now is change our unhealthy diet to a nutritious one, eat less red meat, and have more fibrous foods like green or leafy vegetables, onions, and garlic. We can also take supplements such as prebiotics and probiotics as well. Adding healthy habits in our daily life can help us keep our gut health, which will eventually positively impact our brain health.

    KL: How true is the claim that if viruses and bacterial species will be eliminated from human existence, human survival won’t be the same?

    DZS: That is true to reality. We have millions of bacteria and viruses in our bodies, which have a beneficial role to play. While alive or dead, bacteria are a very valuable assistance to our body. The good bacteria should not be eliminated and the bad ones must also be kept in check.

    After death, the bacteria help decompose the corpse, and while living, it gives aid to our (GI Tract) gastrointestinal system. They release good products like short-chain fatty acids that help in weight loss and gut-related issues. It depends on us to manage the healthy bacteria in our bodies. They are a very important component of our lives.

    (Umaima Reshi processed the interview)

    [ad_2]
    #Gut #Brain

    ( With inputs from : kashmirlife.net )

  • ‘We Have Found Three Inhibitors That Reduce Pain During Cancer’

    [ad_1]

    Dr Muzaffar A Macha has been a ‘golden boy’ throughout. At AIIMS and abroad and now home as head of IUST’s Watson-Crick Centre for Molecular Medicine, after working extensively on head and neck cancers, he has been able to identify an antidote for managing the excruciating pain during all cancers. In a freewheeling conversation with Masood Hussain, the young scientist talks about his research career and the immediate goals he has set for himself and the centre

    KASHMIR LIFE (KL): How was your journey from Kashmir to the USA and then back to Kashmir?

     DR MUZAFFAR A MACHA (MAM): I have done my schooling at Madrassa Taleem-ul Islam (MTI), Tral.  Then I did my bachelor’s in Biochemistry and Environmental Sciences from SP College Srinagar. After that, I went to the Jamia Hamdard for my master’s, which I completed in 2005. I topped there and also received a gold medal.

    Then, I applied to various universities including Jawaharlal Nehru University, All India Institute of Medical Sciences, Indian Institute of Science, CCMB Centre for Cellular and Molecular Biology, and Centre for DNA Fingerprinting and Diagnostics for PhD. I was selected by three Universities, but I choose AIIMS, because of my personal preference and because of the good translational (applications to humans) research work that was being carried out at AIIMS.

    There, I joined the laboratory of Dr Ranju Ralhan. Then I was shifted to another mentor, Sham Singh Chauhan who is the head of AIIMS’s biotechnology department.

    I completed my PhD in 2010 and was awarded with a Gold medal called Gita Mittal Award for the best PhD student with the best publications. My PhD work was mostly about head and neck cancer.

    After that, I went to the University of Nebraska Medical Center for my post-doctorate. There, I joined Dr Surinder Batra, a scientist and a pancreatic cancer specialist. I worked extensively there on cancer biology. Since I had worked on head and neck cancers during my PhD, because of the fact that India has the most cases of this cancer, I started a group to work further on this.

    We continued to work for four and a half years till the completion of my Postdoc. After that, I was inducted there as an Assistant Professor in the same department. I continued there until 2019 and moved back home because of certain family reasons and eagerness to serve my own society.

    After coming back, I applied for the Ramanujan Fellowship and Ramalingaswamy Fellowship and I was selected for both fellowships. I joined the Central University of Kashmir (CUK) as a Ramanujan Fellow.

    A year after working there, I moved to the Watson-Crick Centre for Molecular Medicine of the Islamic University of Science and Technology (IUST). Soon joining as a Ramalingaswami fellow, I was selected as an Assistant professor for Molecular Medicine in the Centre. Presently I am heading the centre.

    KL: Cancer is among the most life-threatening diseases. Where the science is right now in the understanding of cancer?

    MAM: In the last 10 years, the technology that has emerged to identify cancer, to know the cause of cancer and to understand the basic molecular biological concepts proved to be useful and convenient. To a very large extent, we have conquered the battle against cancer. The immunotherapy that is often used these days is yielding good results in treating cancer. Recent studies and clinical trials all over the world proved that immunotherapy is good among all methods for treating cancer.

    The Awantipora Molecule

    KL: You have worked extensively on Head and Neck Cancer during your PhD. What were the major takeaways from the research?

    MAM: As per the studies and statistical data, India has a huge consumption of tobacco products. Head and neck cancer is mostly because of the consumption of tobacco-based products. My research project during my PhD was based on “How cancer is caused by the consumption of Tobacco based products?” I identified cancer development at the molecular and cellular levels. I identified the novel signalling pathways that get activated and lead to cancer.

    Along with this, I identified the usage of natural compounds like Curcumin and Guggulsterone to nullify the effects of smokeless tobacco. These compounds can largely reduce the effects of cancer-causing smokeless tobacco.

    KL: Has there been any kind of comparative study? I mean is the pattern different for cancers caused by smoking and non-smoking cancer agents?

    MAM: It has been studied and is widely accepted all over the world that smokeless tobacco agents mostly cause mouth cancer but smoking usually causes lung cancer. Still, there are cases of people in India and even in Kashmir who have lung cancer even though they had not consumed any smoking or non-smoking product. Thus it is not only the eating habit, which may lead to cancer, although in the majority of cases, it is true but there are genetic causes also. The off-springs of individuals suffering from cancer are more susceptible to cancer because of certain mutations.

    KL: Were your findings accepted by the market and what was the response from academia?

    MAM: During my PhD days, we ran a clinical trial in the department of biochemistry and the department of head and neck Surgery of AIIMS. Patients with head and neck cancer were given Curcumin and the effects were studied. I found out that curcumin prevents cancer to some extent. It also reduces the size and recurrence /regrowth of cancer.

    KL: After completing the successful clinical trials, things usually move to the pharma sector. Is there any such thing based on clinical trials that the market was triggered by your findings?

    MAM: In India, clinical trials were done for curcumin and there are even curcumin derivative compounds in the market that are used as cancer-preventive agents. In the advanced and late stages of cancer, these compounds are not effective but they help in preventing the occurrence of cancer at the early stages.

    KL: You did your Postdoc in the USA, What was your research about, and what were the major takeaways from that?

    MAM: Initially I worked on pancreatic cancer under the mentorship of Dr Surinder Batra. There, I recapitulated the findings of my PhD work, that is how the natural compounds can prevent the development of cancer and decrease cancer-causing active signalling pathways present in head and neck cancer. I attempted to use the same for pancreatic cancer. My other colleague was working on a molecule called Mucin (MUC4). The findings of my PhD proved that Guggulsterone decreases the expression of Mucin/MUC4.

    Expression of Muc4 in the cells increases the tendency of having more aggressive and proliferative cancer. My research study was to reduce the proliferation (Metastasis) and aggressiveness of cancer cells using Guggulsterone.

    After that, I created a group of dedicated people to study head and neck cancer. I also came to know that MUC4 is expressed in around 90 per cent of cancer patients, and it causes drug resistance against cancer with time. I came to know that MUC4 is an important factor in the development and metastasis of both pancreatic as well as head and neck cancer.

    DR Muzaffar A Macha WCCMM IUST
    Dr Muzaffar A Macha (WCCMM-IUST)

    KL: What was the follow-up of your research? You must be in touch with the labs still because the scientific community remains in touch with each other. Has there been any kind of formal movement to what you did during your Postdoc?

    MAM: No one worked on the MUC4 for quite a long time, but when I was inducted as an Assistant Professor, I started to work on one more molecule called NR4A2 (a transcription factor). I concluded that this molecule has a major role in causing intense pain during cancer. I along with other colleagues are working to design an inhibitor against it. We have identified three inhibitors and we are going to publish this very soon. Inhibitors reduce pain across all cancer patients to a very large extent.

    Besides, we found that the pain in pancreatic cancer due to the Perineural-invasion (i.e., Cancer cells penetrate into the nerve cells), is also because of the NR4A2 molecule and can be cured with the help of inhibitors.

    KL: You are currently working at the Watson-Crick Center for Molecular Medicine of the IUST. What is your individual research focus there?

    MAM: In Kashmir particularly, gastrointestinal tract cancers like oesophageal cancer, stomach cancer, and colorectal cancer are more common in people among all the cancers. Kashmir has the third highest number of oesophageal cancer patients all over the world after China and some areas of Iran.

    Although there has been a lot of research work on colorectal cancer and oesophageal cancer, but the actual biology and high throughput technology have not been used here in Kashmir until now. We still do not have the cell-line models and animal models which are necessary to study cancer.

    My current project under the Ramalingaswami Fellowship is to develop in-vitro models in order to better study oesophageal and gastric cancers. These models can be used to study the underlying biology and molecular biology of cancer.

    KL: Since your Centre is newly established, what is the present state and status of its infrastructure?

    MAM: The Watson-Crick Centre for Molecular Medicine started in 2018 but the faculty recruitment was done in 2020. I along with my colleagues like Dr Rais and Dr Arsheed joined in 2020. We started from zero. There was very little infrastructure around and within less than two years, we achieved a great feat. It is all with the help from the higher authorities at the IUST. We now are at the stage of working at an extensive pace and for longer durations. Earlier we had the limitation of culture rooms here but now we almost have everything to do full-fledged research.

    KL: Do you have the limitation of any major equipment because high-end research essentially needs sophisticated machinery?

    MAM: We do not have high-end and high-throughput machinery, but we have basic instruments. We have procured many instruments and machines and we are in the process of procuring many other. We have an allotment of around Rs 6 crore of funding grants of which Rs 1 crore is for procuring instruments. Projects that require high-end instruments are mostly being done in collaboration with other departments or are outsourced.

    KL: Many times more than one university work on the same research topic, but every university has a different vision and different priority. Is any other institution in Kashmir working on the same topic as you do?

    MAM: As such, there is only one scientist at Sheri Kashmir Institute of Medical Sciences working on the in-vitro models, but I do not know what stage has he reached. Importantly it is worth knowing whether you have the expertise for the research or not. During my Postdoc and Assistant professorship, I have personally made many in-vitro models, so I have the expertise to carry forward that work in our Center at the IUST.

    .. Mujtaba Hussain processed the interview

    [ad_2]
    #Inhibitors #Reduce #Pain #Cancer

    ( With inputs from : kashmirlife.net )